Literature DB >> 12719624

Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease.

Francisco García-Sierra1, Nupur Ghoshal, Bruce Quinn, Robert W Berry, Lester I Binder.   

Abstract

The conformation-dependent antibodies Tau-66 and Alz-50 recognize discontinuous epitopes on the tau molecule (residues 155-244 & 305-314 and 5-15 & 312-322, respectively), thereby defining two distinct conformations. In double- and triple-label immunofluorescence experiments we discovered that specific populations of neurofibrillary tangles display either the Alz-50 or the Tau-66 conformation, but not both. In combination with other antibodies to several domains of the molecule we demonstrate that the conformation recognized by Alz-50 seems to be an early event in the formation of neurofibrillary tangles. This conformation is characterized by the presence of predominantly intact N- and C- termini. By contrast, the Tau-66 conformation is likely a later event in tangle development, being favored in structures containing truncations of both the N- and C- termini. We propose a sequence of events that occurs during the formation and evolution of neurofibrillary tangles based on the initial conformation adopted by tau. In this scheme, the Tau-66 conformation in neurofibrillary tangles may arise from amino and carboxy truncation of tau after it has assumed the Alz-50 conformation. These results indicate that tau structure within the NFT is dynamic in that tau can undergo a "refolding" event following N- and C-terminal truncation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719624     DOI: 10.3233/jad-2003-5201

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  49 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

2.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

3.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

4.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

5.  Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Ismael Santa-Maria; Raúl Mena; Lester I Binder; Jesús Avila; Mark A Smith; George Perry; Francisco García-Sierra
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

6.  Cortical and hippocampal neurons from truncated tau transgenic rat express multiple markers of neurodegeneration.

Authors:  Peter Filipcik; Martin Cente; Gabriela Krajciova; Ivo Vanicky; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

7.  Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.

Authors:  Chelsea T Tiernan; Stephen D Ginsberg; Bin He; Sarah M Ward; Angela L Guillozet-Bongaarts; Nicholas M Kanaan; Elliott J Mufson; Scott E Counts
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

Review 8.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

9.  Memantine prevents sensitivity to excitotoxic cell death of rat cortical neurons expressing human truncated tau protein.

Authors:  Martin Cente; Stanislava Mandakova; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2009-03-17       Impact factor: 5.046

10.  A possible link between astrocyte activation and tau nitration in Alzheimer's disease.

Authors:  Juan F Reyes; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Angela L Guillozet-Bongaarts; Robert Berry; Lester I Binder
Journal:  Neurobiol Dis       Date:  2008-05-02       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.